RT Journal Article
SR Electronic
T1 Low Intensity Vibration Protects the Weight Bearing Skeleton and Suppresses Fracture Incidence in Boys with Duchenne Muscular Dystrophy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.12.22273806
DO 10.1101/2022.04.12.22273806
A1 Bianchi, ML
A1 Vai, S
A1 Baranello, G
A1 Broggi, F
A1 Judex, S
A1 Hangartner, TN
A1 Rubin, CT
YR 2022
UL http://medrxiv.org/content/early/2022/04/13/2022.04.12.22273806.abstract
AB Introduction/Aims The ability of low intensity vibration (LIV) to combat skeletal decline in Duchenne Muscular Dystrophy (DMD) was evaluated in a randomized controlled trial.Methods Twenty DMD boys were enrolled, all ambulant and treated with glucocorticoids (mean age 7.6, height-adjusted Z-scores (HAZ) of hip BMD −2.3). Ten DMD boys were assigned to stand for 10min/d on an Active LIV platform (0.4g @ 30Hz), while 10 stood on a Placebo device. Baseline and 14-month BMC and BMD of spine, hip and total body were measured with DXA, and trabecular bone density (TBD) of tibia with QCT.Results All children tolerated the LIV intervention well, with daily compliance averaging 78%. At 14 months, TBD in the proximal and distal tibia remained unchanged in Placebo (−0.7% & −0.8%), while rising 4.1% and 4.5% in LIV. HAZ for hip BMD and BMC in Placebo declined 22% and 13% respectively, contrasting with no change from baseline (0.9% and 1.4%) in LIV. Fat mass in the leg increased 33% in Placebo, contrasting with 20% in LIV subjects. Across the 14-month study, there were four incident fractures in three placebo patients (30%), with no new fractures identified in LIV subjects.Conclusions These data suggest that non-invasive LIV can help protect the skeleton of DMD children against the disease progression, the consequences of diminished load bearing, and the complications of chronic steroid use.Competing Interest StatementCTR and SJ have several US and International patents issued on the use of low intensity vibration for the treatment of musculoskeletal injury and disease. CTR is also a founder of Marodyne, Inc, who developed the LIV platform for clinical use as LivMD. No other authors have any conflicts to report.Clinical TrialNCT05281120Funding StatementWe are grateful to the Istituto Auxologico Italiano IRCCS, Milan, Italy, for providing funding for the study, and to Mr. Ian Cutts, COPA Healthcare, for the generous loan of the prototype LIV devices.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Istituto Auxologico Italiano IRCCS, Milan, Italy, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors